Drugs / VALETHAMATE
VALETHAMATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07474350 | Sep 2023 → Jan 2024 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VALETHAMATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111176 ↗ |
| Known as | Epidosin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111176 ↗ |
| Known as | Resitan | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111176 ↗ |
| Known as | Valethamate Bromide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07474350 ↗ |
| Known as | Valethamate cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111176 ↗ |
| Known as | Valethamate ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL2111176 ↗ |
| Modality | Small molecule | — CHEMBL2111176 ↗ |
| Route | Intravenous | “Two ml (16mg) of valethamate bromide was given intravenously to the patient who has attained active phase labour parameters” NCT07474350 ↗ |